Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Jeffrey S WeberDirk SchadendorfMichele Del VecchioJames M G LarkinVictoria AtkinsonMichael SchenkerJacopo PigozzoHelen J GogasStéphane DalleNicolas MeyerPaolo Antonio AsciertoShahneen SandhuThomas EigentlerRalf GutzmerJessica C HasselCaroline RobertMatteo S CarlinoAnna Maria Di GiacomoMarcus O ButlerEva Muñoz CouseloMichael P BrownPiotr Lukasz RutkowskiAndrew M HaydonJean-Jacques GrobJacob SchachterPaola QueiroloLuis de la Cruz MerinoAndre van der WesthuizenAlexander M MenziesSandra ReTuba BasVeerle de PrilJulia BravermanDaniel J TenneyHao TangGeorgina V LongPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Nivolumab 240 mg once every 2 weeks plus ipilimumab 1 mg/kg once every 6 weeks did not improve RFS versus nivolumab 480 mg once every 4 weeks in patients with stage IIIB-D or stage IV melanoma. Nivolumab showed efficacy consistent with previous adjuvant studies in a population resembling current practice using American Joint Committee on Cancer eighth edition, reaffirming nivolumab as a standard of care for melanoma adjuvant treatment.